Media Vertigo score (MVS) 15 days [clinicaltrials_resource:7635dc4a16d4a4e20b5a16c5051e34e9]
Evaluation of efficacy by varying the Media Vertigo score (MVS) which is the average of the intensities of vertigo symptoms described at Visit 1, assigning the scores to 0-4 categories None, Mild, Moderate, Strong, Very Strong, respectively. The primary hypothesis is the non-inferiority of Meclizine chlorhydrate regarding Dimenidrinato in reducing the MVS V1 to V2.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Media Vertigo score (MVS) 15 days [clinicaltrials_resource:7635dc4a16d4a4e20b5a16c5051e34e9]
Evaluation of efficacy by varying the Media Vertigo score (MVS) which is the average of the intensities of vertigo symptoms described at Visit 1, assigning the scores to 0-4 categories None, Mild, Moderate, Strong, Very Strong, respectively. The primary hypothesis is the non-inferiority of Meclizine chlorhydrate regarding Dimenidrinato in reducing the MVS V1 to V2.
Bio2RDF identifier
7635dc4a16d4a4e20b5a16c5051e34e9
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:7635dc4a16d4a4e20b5a16c5051e34e9
measure [clinicaltrials_vocabulary:measure]
Media Vertigo score (MVS)
time frame [clinicaltrials_vocabulary:time-frame]
description
Evaluation of efficacy by vary ...... in reducing the MVS V1 to V2.
identifier
clinicaltrials_resource:7635dc4a16d4a4e20b5a16c5051e34e9
title
Media Vertigo score (MVS) 15 days
@en
type
label
Media Vertigo score (MVS) 15 d ...... 5dc4a16d4a4e20b5a16c5051e34e9]
@en